BR112013012710A2 - método de isolamento de uma célula de câncer resistente a agente quimioterápico com propriedades de célula tronco - Google Patents

método de isolamento de uma célula de câncer resistente a agente quimioterápico com propriedades de célula tronco

Info

Publication number
BR112013012710A2
BR112013012710A2 BR112013012710A BR112013012710A BR112013012710A2 BR 112013012710 A2 BR112013012710 A2 BR 112013012710A2 BR 112013012710 A BR112013012710 A BR 112013012710A BR 112013012710 A BR112013012710 A BR 112013012710A BR 112013012710 A2 BR112013012710 A2 BR 112013012710A2
Authority
BR
Brazil
Prior art keywords
isolating
chemotherapeutic agent
stem cell
cancer cell
resistant cancer
Prior art date
Application number
BR112013012710A
Other languages
English (en)
Other versions
BR112013012710B1 (pt
Inventor
Barry Smith
Lawrence Ggazda
Original Assignee
Rogosin Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rogosin Inst Inc filed Critical Rogosin Inst Inc
Publication of BR112013012710A2 publication Critical patent/BR112013012710A2/pt
Publication of BR112013012710B1 publication Critical patent/BR112013012710B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/76—Agarose, agar-agar
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

método de isolamento de uma célula de câncer resistente a agente quimioterápico com propriedades de célula tronco. a invenção refere-se ao uso de encapsulados de células de câncer, em microesferas que contêm agarose e são revestidos com agarose, para isolar células resistentes a quimioterapia que têm pelo menos uma propriedade de célula tronco, tal como expressão de oct4. as células assim isoladas são também um recurso da invenção, assim como um método para selecionar para potencial terapêutico.
BR112013012710-4A 2010-11-23 2011-11-22 método de isolamento de uma célula de câncer resistente a agente quimioterápico com propriedades de célula tronco BR112013012710B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45839010P 2010-11-23 2010-11-23
US45839110P 2010-11-23 2010-11-23
US61/458,390 2010-11-23
US61/458,391 2010-11-23
PCT/US2011/061812 WO2012071394A1 (en) 2010-11-23 2011-11-22 Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties

Publications (2)

Publication Number Publication Date
BR112013012710A2 true BR112013012710A2 (pt) 2016-07-12
BR112013012710B1 BR112013012710B1 (pt) 2021-03-09

Family

ID=46146185

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012710-4A BR112013012710B1 (pt) 2010-11-23 2011-11-22 método de isolamento de uma célula de câncer resistente a agente quimioterápico com propriedades de célula tronco

Country Status (20)

Country Link
US (2) US8741637B2 (pt)
EP (2) EP2777398B1 (pt)
JP (1) JP5899230B2 (pt)
KR (1) KR101874654B1 (pt)
CN (1) CN103108547B (pt)
AP (1) AP3446A (pt)
AU (1) AU2011332020B2 (pt)
BR (1) BR112013012710B1 (pt)
CA (1) CA2801370C (pt)
DK (2) DK2777398T3 (pt)
ES (2) ES2632066T3 (pt)
HK (1) HK1179827A1 (pt)
HU (1) HUE035164T2 (pt)
IL (2) IL223362A (pt)
MX (1) MX2013005836A (pt)
NZ (1) NZ603949A (pt)
PL (2) PL2777398T3 (pt)
PT (2) PT2597952E (pt)
RU (1) RU2583296C2 (pt)
WO (1) WO2012071394A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19511572C2 (de) * 1995-03-29 1998-02-26 Henkel Kgaa Niedrigviskose Trübungsmittelkonzentrate
US6303151B1 (en) 1996-04-03 2001-10-16 The Rogosin Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US6224912B1 (en) 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US7297331B2 (en) 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
US5888497A (en) * 1996-04-03 1999-03-30 The Rogosin Institute Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation
US20050053586A1 (en) * 2003-09-04 2005-03-10 Bryan Conn Entrapped stem cells and uses thereof
AU2006295114B2 (en) 2005-09-26 2010-01-28 The Rogosin Institute, Inc. Secretory cell-containing macrobeads comprising Seakem Gold agarose, and uses thereof
US7704967B2 (en) * 2006-03-14 2010-04-27 University Of Maryland, Baltimore TFIIS and GDOWN1 as targets for cancer therapy
US20070254319A1 (en) * 2006-04-07 2007-11-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of a constitutively resistant cancer stem cell
KR100783199B1 (ko) * 2006-05-18 2007-12-06 부산대학교 산학협력단 인간의 뇌 암 조직으로부터 확립된 신규 암 줄기 세포주ｇｂｍ 2
EP2081590A4 (en) * 2006-09-07 2011-12-28 Stemline Therapeutics Inc CANCER THERAPY TREATED AGAINST CANCER STEM CELLS
EP2190481B1 (en) * 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
EP3095470A1 (en) * 2008-02-07 2016-11-23 Shahar Cohen Compartmental extract compositions for tissue engineering
WO2010119001A1 (en) * 2009-04-14 2010-10-21 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
WO2010124498A1 (en) * 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine

Also Published As

Publication number Publication date
EP2597952A4 (en) 2014-01-22
DK2777398T3 (en) 2017-06-26
KR20130132741A (ko) 2013-12-05
CN103108547B (zh) 2015-09-02
US8741637B2 (en) 2014-06-03
RU2583296C2 (ru) 2016-05-10
CA2801370A1 (en) 2012-05-31
MX2013005836A (es) 2013-07-05
JP2014507931A (ja) 2014-04-03
RU2012151922A (ru) 2014-12-27
EP2597952B1 (en) 2015-01-07
PT2777398T (pt) 2017-07-21
JP5899230B2 (ja) 2016-04-06
DK2597952T3 (en) 2015-03-30
IL233227A0 (en) 2014-07-31
US20140234440A1 (en) 2014-08-21
NZ603949A (en) 2014-03-28
PT2597952E (pt) 2015-04-29
AP3446A (en) 2015-10-31
US9375448B2 (en) 2016-06-28
PL2777398T3 (pl) 2017-09-29
BR112013012710B1 (pt) 2021-03-09
EP2597952A1 (en) 2013-06-05
AP2013006904A0 (en) 2013-06-30
CN103108547A (zh) 2013-05-15
ES2534374T3 (es) 2015-04-22
PL2597952T3 (pl) 2015-07-31
HK1179827A1 (zh) 2013-10-11
AU2011332020A1 (en) 2012-12-20
WO2012071394A1 (en) 2012-05-31
AU2011332020B2 (en) 2014-03-13
CA2801370C (en) 2018-03-06
EP2777398A1 (en) 2014-09-17
HUE035164T2 (en) 2018-05-02
EP2777398B1 (en) 2017-04-12
IL223362A (en) 2016-04-21
ES2632066T3 (es) 2017-09-08
IL233227A (en) 2017-07-31
US20130244248A1 (en) 2013-09-19
KR101874654B1 (ko) 2018-07-04

Similar Documents

Publication Publication Date Title
PH12015502819A1 (en) Anti-pd-1 antibody and use thereof
IL240881A0 (en) Expression of the t cell balance gene, preparations, materials and methods for its use
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
CY1120304T1 (el) Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας
BR112016015105A2 (pt) Conjugados var2csa-droga
ECSP14013339A (es) Compuestos con actividad nematicida
EP3102609A4 (en) Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
CL2008002873A1 (es) Anticuerpo anti-glipican 3/gpc3; composicion que lo comprende; agente anti-canceroso que lo comprende; acido nucleico que codifica dicho anticuerpo; celula hospedera aislada que comprende dicho acido nucleico; metodo para la preparacion de dicho anticuerpo
DOP2014000090A (es) Compuestos con actividad nematicida
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
UY35500A (es) Indazoles sustituidos con heteroarilo
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
ECSP11011466A (es) Anticuerpos específicos para cadherina-17
BR112016012595A2 (pt) método de produzir (r)-reticulina ou um precursor de (r)-reticulina; método de preparar (r)-reticulina ou um precursor de (r)-reticulina; composição para produzir (r)-reticulina ou precursor de (r)-reticulina; vetor de expressão recombinante; método de detectar a presença ou ausência de uma sequência de ácidos nucleicos codificando akr e/ou cyp450 em uma célula; método para modular expressão de sequências de ácidos nucleicos em uma célula naturalmente expressando akr e/ou cyp450; método para produzir uma planta que produz semente; e; utilização de uma sequência de ácidos nucleicos codificando akr ou cyp450
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
EP3013944A4 (en) Composition of mesenchymal stem cells
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
SG10201706813WA (en) Culture medium for proliferating stem cell, which contains sulfated compound
BR112012015677A2 (pt) Compostos farmacêuticos.
EP3488482A4 (en) INTERMEDIATE TEMPERATURE FUEL CELL SUITABLE FOR EFFICIENT USE OF METHANE
CU24420B1 (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112016015820A2 (pt) Transformante para expressar cis-preniltransferase e receptor nogo b

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/11/2011, OBSERVADAS AS CONDICOES LEGAIS.